論文・出版物 - 2004

Mizuguchi H., Hayakawa T., Targeted adenovirus vectors. Hum. Gene Ther., 15, 1034-1044 (2004) PubMed

​

Hosono T., Mizuguchi H., Katayama K., Xu ZL., Sakurai F., Ishii-Watabe A., Kawabata K., Yamaguchi T., Nakagawa S., Mayumi T., Hayakawa T. Adenovirus vector-mediated doxycycline-inducible RNA interference. Hum. Gene Ther., 15, 813-819 (2004) PubMed

Koizumi, N., Mizuguchi H., Kondoh, M., Fujii, M., Hayakawa, T., Watanabe, Y. Efficient gene transfer into human trophoblast cells with adenovirus vector containing chimeric type 5 and 35 fiber protein. Biol. Pharm. Bull., 27, 2046-2048 (2004) PubMed

Uchida E., Sato K., Iwata A., Ishii-Watabe A., Mizuguchi H., Hikata M., Murata M., Yamaguchi T., Hayakawa T. An improved method for detection of replication-competent retrovirus in retrovirus vector products. Biologicals, 32, 139-146 (2004) PubMed

Gao J-Q., Inoue S., Tsukada Y., Katayama K., Eto Y., Kurachi S., Mizuguchi H., Hayakawa T., Tsutsumi Y., Mayumi T., Nakagawa S. High gene expression of the mutant adenovirus vector, both in vitro and in vivo, with the insertion of integrin-targeting peptide into the fiber. Pharmazie, 59, 571-572 (2004) PubMed

Kawai H., Suzuki T., Kobayashi T., Mizuguchi H., Hayakawa T., Kawanishi T. Simultaneous imaging of initiator/effector caspase activity and mitochondrial membrane potential during cell death in living HeLa cells. Biochim. Biophys. Acta., 1693, 101-110 (2004) PubMed

Eto Y., Gao J-Q., Sekiguchi F., Kurachi S., Katayama K., Mizuguchi H., Hayakawa T., Tsutsumi Y., Mayumi T., Nakagawa S. Neutralizing antibody evasion ability of adenovirus vector induced by the bioconjugation of methoxypolyethylene glycol succinimidyl propionate (MPEG-SPA). Biol. Pharm. Bull., 27, 936-938 (2004) PubMed

Nakamura T., Peng K-W., Vongpunsawad S., Harvey M., Mizuguchi H., Hayakawa T., Cattaneo R., Russell S.J. Antibody-targeted cell fusion. Nat. Biotech., 22, 331-336 (2004) PubMed

Okada Y., Okada N., Mizuguchi H., Takahashi K., Hayakawa T., Mayumi T., Mizuno N. Optimization of antitumor efficacy and safety of in vivo cytokine gene therapy using RGD fiber-mutant adenovirus vector for preexisting murine melanoma. Biochim. Biophys. Acta., 1670, 172-180 (2004) PubMed

Okada N., Gao J-Q., Sasaki A., Niwa M., Okada Y., Nakayama T., Yoshie O., Mizuguchi H., Hayakawa T., Fujita T., Yamamoto A., Tsutsumi Y., Mayumi T., Nakagawa S. Anti-tumor activity of chemokine is affected by both kinds of tumors and the activation state of the host's immune system: implications for chemokine-based cancer immunotherapy. Biochem. Biophys. Res. Commun., 317, 68-76 (2004) PubMed

Anno T., Uehara S., Katagiri H., Ohta Y., Ueda K., Mizuguchi H., Moriyama Y., Oka Y., Tanizawa Y. Overexpression of constitutively activated glutamate dehydrogenase induces insulin secretion through enhanced glutamate oxidation. Am. J. Physiol., 286, E280-285 (2004) PubMed

Gao J-Q, Alexandre L.S., Tsuda Y., Katayama K., Eto Y., Sekiguchi F., Mizuguchi H., Hayakawa T., Nakayama T., Yoshie O., Tsutsumi Y., Mayumi T., Nakagawa S. Tumor-suppressive activities by chemokines introduced into OV-HM cells using fiber-mutant adenovirus vectors. Pharmazie, 59, 238-239 (2004) PubMed

Katayama K., Wada K., Miyoshi H., Ohashi K., Tachibana M., Furuki R., Mizuguchi H., Hayakawa T., Nakajima A., Kadowaki T., Tsutsumi Y., Nakagawa1 S., Kamisaki Y., Mayumi T. RNA interfering approach for clarifying PPARγ pathway using lentiviral vector expressing short hairpin RNA. FEBS Lett., 560, 178-182 (2004) PubMed

Suto R., Tominaga K., Mizuguchi H., Sasaki E., Higuchi K., Kim S., Iwao H., Arakawa T. Dominant negative mutant of c-Jun gene transfer: a novel therapeutic strategy for colorectal cancer. Gene Ther., 11, 187-193 (2004) PubMed

水口裕之、早川堯夫；アデノウイルスベクター、Mebio、21(4)、8-16 (2004)

​

​